Article
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.
International journal of hematology - 1 Nov 2022
Morita Yasuyoshi, Nannya Yasuhito, Ichikawa Motoshi, Hanamoto Hitoshi, Shibayama Hirohiko, Maeda Yoshinobu, Hata Tomoko, Miyamoto Toshihiro, Kawabata Hiroshi, Takeuchi Kazuto, Tanaka Hiroko, Kishimoto Junji, Miyano Satoru, Matsumura Itaru, Ogawa Seishi, Akashi Koichi, Kanakura Yuzuru, Mitani Kinuko
Abstract excerpt
Darbepoetin alfa (DA) is used to treat anemia in lower-risk (IPSS low or int-1) myelodysplastic syndromes (MDS). However, whether mutations can predict the effectiveness of DA has not been examined. The present study aimed to determine predictive gene mutations. The primary endpoint was a correlation between the presence of highly frequent (≥ 10%) mutations and hematological improvement-erythroid according to IWG...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.